Latest Breaking News On - Urological association annual - Page 1 : comparemela.com

Most BCG-Unresponsive Bladder Cancer Responds to TAR-200 Treatment

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC

UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.